Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $137.5 million.

  • Adma Biologics' Total Liabilities fell 1337.32% to $137.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.5 million, marking a year-over-year decrease of 1337.32%. This contributed to the annual value of $139.7 million for FY2024, which is 2800.14% down from last year.
  • As of Q3 2025, Adma Biologics' Total Liabilities stood at $137.5 million, which was down 1337.32% from $160.1 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Total Liabilities ranged from a high of $200.2 million in Q3 2022 and a low of $121.2 million during Q2 2021
  • Its 5-year average for Total Liabilities is $167.2 million, with a median of $181.1 million in 2022.
  • As far as peak fluctuations go, Adma Biologics' Total Liabilities surged by 5057.86% in 2022, and later plummeted by 3044.04% in 2025.
  • Over the past 5 years, Adma Biologics' Total Liabilities (Quarter) stood at $135.1 million in 2021, then soared by 45.46% to $196.5 million in 2022, then dropped by 1.28% to $194.0 million in 2023, then dropped by 28.0% to $139.7 million in 2024, then dropped by 1.55% to $137.5 million in 2025.
  • Its Total Liabilities stands at $137.5 million for Q3 2025, versus $160.1 million for Q2 2025 and $137.2 million for Q1 2025.